ABSTRACT
BACKGROUND: Myxomatous valve disease (MVD) is the most common cause of mitral regurgitation, leading to impaired cardiac function and heart failure. MVD in a mouse model of Marfan syndrome includes valve leaflet thickening and progressive valve degeneration. However, the underlying mechanisms by which the disease progresses remain undefined. METHODS: Mice with Fibrillin 1 gene variant Fbn1C1039G/+ recapitulate histopathologic features of Marfan syndrome, and Wnt (Wingless-related integration site) signaling activity was detected in TCF/Lef-lacZ (T-cell factor/lymphoid enhancer factor-ß-galactosidase) reporter mice. Single-cell RNA sequencing was performed from mitral valves of wild-type and Fbn1C1039G/+ mice at 1 month of age. Inhibition of Wnt signaling was achieved by conditional induction of the secreted Wnt inhibitor Dkk1 (Dickkopf-1) expression in periostin-expressing valve interstitial cells of Periostin-Cre; tetO-Dkk1; R26rtTA; TCF/Lef-lacZ; Fbn1C1039G/+ mice. Dietary doxycycline was administered for 1 month beginning with MVD initiation (1-month-old) or MVD progression (2-month-old). Histological evaluation and immunofluorescence for ECM (extracellular matrix) and immune cells were performed. RESULTS: Wnt signaling is activated early in mitral valve disease progression, before immune cell infiltration in Fbn1C1039G/+ mice. Single-cell transcriptomics revealed similar mitral valve cell heterogeneity between wild-type and Fbn1C1039G/+ mice at 1 month of age. Wnt pathway genes were predominantly expressed in valve interstitial cells and valve endothelial cells of Fbn1C1039G/+ mice. Inhibition of Wnt signaling in Fbn1C1039G/+ mice at 1 month of age prevented the initiation of MVD as indicated by improved ECM remodeling and reduced valve leaflet thickness with decreased infiltrating macrophages. However, later, Wnt inhibition starting at 2 months did not prevent the progression of MVD. CONCLUSIONS: Wnt signaling is involved in the initiation of mitral valve abnormalities and inflammation but is not responsible for later-stage valve disease progression once it has been initiated. Thus, Wnt signaling contributes to MVD progression in a time-dependent manner and provides a promising therapeutic target for the early treatment of congenital MVD in Marfan syndrome.
Subject(s)
Disease Models, Animal , Disease Progression , Fibrillin-1 , Mitral Valve , Wnt Signaling Pathway , Animals , Fibrillin-1/genetics , Fibrillin-1/metabolism , Mitral Valve/metabolism , Mitral Valve/pathology , Mitral Valve/drug effects , Mice , Intercellular Signaling Peptides and Proteins/metabolism , Intercellular Signaling Peptides and Proteins/genetics , Mice, Transgenic , Marfan Syndrome/genetics , Marfan Syndrome/complications , Marfan Syndrome/metabolism , Marfan Syndrome/pathology , Mitral Valve Insufficiency/pathology , Mitral Valve Insufficiency/metabolism , Mitral Valve Insufficiency/prevention & control , Mitral Valve Insufficiency/genetics , Mice, Inbred C57BL , Inflammation/metabolism , Inflammation/pathology , Inflammation/prevention & control , Inflammation/genetics , Male , Female , Cell Adhesion Molecules , AdipokinesABSTRACT
Subjects with asymptomatic moderate-to-severe or severe primary mitral regurgitation are closely observed for signs of progression or symptoms requiring surgical intervention. The role of myocardial metabolic function in progression of mitral regurgitation is poorly understood. We used 11C-acetate PET to noninvasively measure myocardial mechanical external efficiency (MEE), which is the energetic ratio of external cardiac work and left ventricular (LV) oxygen consumption. Methods: Forty-seven patients in surveillance with mitral regurgitation and no or minimal symptoms prospectively underwent PET, echocardiography, and cardiac MRI on the same day. PET was used to simultaneously measure cardiac output, LV mass, and oxygen consumption to establish MEE. PET findings were compared between patients and healthy volunteers (n = 9). MEE and standard imaging indicators of regurgitation severity, LV volumes, and function were studied as predictors of time to surgical intervention. Patients were followed a median of 3.0 y (interquartile range, 2.0-3.8 y), and the endpoint was reached in 22 subjects (47%). Results: MEE in patients reaching the endpoint (23.8% ± 5.0%) was lower than in censored patients (28.5% ± 4.5%, P = 0.002) or healthy volunteers (30.1% ± 4.9%, P = 0.001). MEE with a cutoff lower than 25.7% was significantly associated with the outcome (hazard ratio, 7.5; 95% CI, 2.7-20.6; P < 0.0001) and retained independent significance when compared with standard imaging parameters. Conclusion: MEE independently predicted time to progression requiring valve surgery in patients with asymptomatic moderate-to-severe or severe primary mitral regurgitation. The study suggests that inefficient myocardial oxidative metabolism precedes clinically observed progression in mitral regurgitation.
Subject(s)
Mitral Valve Insufficiency , Humans , Mitral Valve Insufficiency/diagnostic imaging , Mitral Valve Insufficiency/metabolism , Heart/diagnostic imaging , Myocardium/metabolism , Positron-Emission Tomography/methods , Acetates/metabolism , Ventricular Function, LeftABSTRACT
Degenerative mitral valve (MV) regurgitation (MR) is a highly prevalent heart disease that requires surgery in severe cases. Here, we show that a decrease in the activity of the serotonin transporter (SERT) accelerates MV remodeling and progression to MR. Through studies of a population of patients with MR, we show that selective serotonin reuptake inhibitor (SSRI) use and SERT promoter polymorphism 5-HTTLPR LL genotype were associated with MV surgery at younger age. Functional characterization of 122 human MV samples, in conjunction with in vivo studies in SERT-/- mice and wild-type mice treated with the SSRI fluoxetine, showed that diminished SERT activity in MV interstitial cells (MVICs) contributed to the pathophysiology of MR through enhanced serotonin receptor (HTR) signaling. SERT activity was decreased in LL MVICs partially because of diminished membrane localization of SERT. In mice, fluoxetine treatment or SERT knockdown resulted in thickened MV leaflets. Similarly, silencing of SERT in normal human MVICs led to up-regulation of transforming growth factor ß1 (TGFß1) and collagen (COL1A1) in the presence of serotonin. In addition, treatment of MVICs with fluoxetine not only directly inhibited SERT activity but also decreased SERT expression and increased HTR2B expression. Fluoxetine treatment and LL genotype were also associated with increased COL1A1 expression in the presence of serotonin in MVICs, and these effects were attenuated by HTR2B inhibition. These results suggest that assessment of both 5-HTTLPR genotype and SERT-inhibiting treatments may be useful tools to risk-stratify patients with MV disease to estimate the likelihood of rapid disease progression.
Subject(s)
Mitral Valve Insufficiency , Mitral Valve , Humans , Animals , Mice , Mitral Valve/metabolism , Mitral Valve Insufficiency/metabolism , Fluoxetine/pharmacology , Fluoxetine/therapeutic use , Fluoxetine/metabolism , Serotonin Plasma Membrane Transport Proteins/genetics , Serotonin Plasma Membrane Transport Proteins/metabolism , Serotonin/metabolism , Serotonin/pharmacology , Selective Serotonin Reuptake Inhibitors/pharmacology , Selective Serotonin Reuptake Inhibitors/therapeutic useABSTRACT
Patients with primary mitral regurgitation (MR) may remain asymptomatic for many years. For unknown reasons, some shift from a compensated to a decompensated state and progress to fatal heart failure. To elucidate the genetic determinants of this process, we recruited 28 patients who underwent mitral valve surgery and stratified them into control, compensated MR, and decompensated MR groups. Tissue biopsies were obtained from the patients' left ventricular (LV) lateral wall for a transcriptome-wide profiling of 64,769 probes to identify differentially expressed genes (DEGs). Using cutoff values at the 1% FDR significance level and sex- and age-adjusted regression models, we identified 12 significant DEGs (CTGF, MAP1B, SERPINE1, MYH9, MICAL2, MYO1D, CRY1, AQP7P3, HTRA1, PRSS23, IGFBP2, and FN1). The most significant gene was CTGF (adjusted R2 = 0.74, p = 1.80 × 10-8). We found that the majority of genes expressed in the more advanced decompensated MR group were pro-fibrotic genes associated with cardiac fibrosis. In particular, six pro-fibrotic genes (CTGF, SERPINE1, MYH9, HTRA1, PRSS23, and FN1) were overexpressed and enriched in pathways involved in ECM (extracellular matrix) protein remodeling. Therapeutic interventions that antagonize these six genes may slow the progression toward decompensated MR.
Subject(s)
Heart Ventricles/metabolism , Mitral Valve Insufficiency/metabolism , Mitral Valve Insufficiency/physiopathology , Ventricular Dysfunction, Left/physiopathology , Aged , Biopsy , Extracellular Matrix/metabolism , Female , Gene Expression Profiling , Gene Expression Regulation , Humans , Male , Middle Aged , Mitral Valve/pathology , Mitral Valve Insufficiency/complications , Oligonucleotide Array Sequence Analysis , Regression Analysis , Stroke Volume , Transcriptome , Ventricular Dysfunction, Left/complications , Ventricular Function, Left , Ventricular Remodeling/geneticsABSTRACT
[Figure: see text].
Subject(s)
Bone Morphogenetic Protein 4/metabolism , Leukocyte Common Antigens/metabolism , Mitral Valve Insufficiency/metabolism , Mitral Valve/drug effects , Myocardial Infarction/metabolism , Transforming Growth Factor beta1/pharmacology , Animals , Cells, Cultured , Disease Models, Animal , Female , Gene Regulatory Networks , Leukocyte Common Antigens/genetics , Male , Mitral Valve/metabolism , Mitral Valve/pathology , Mitral Valve/physiopathology , Mitral Valve Insufficiency/genetics , Mitral Valve Insufficiency/pathology , Mitral Valve Insufficiency/physiopathology , Myocardial Infarction/genetics , Myocardial Infarction/pathology , Myocardial Infarction/physiopathology , Protein Interaction Maps , Sheep, Domestic , Signal Transduction , Transcriptome , Ventricular Function, Left , Ventricular RemodelingABSTRACT
This study aimed to explore the potential target of the cardio-protective effect induced by sevoflurane anesthesia based on evidence from clinical samples and in vitro model. Forty patients undergoing mitral valve replacement were randomly allocated to receive sevoflurane or propofol-based anesthesia. Atrial muscle specimens were collected from all patients, of which 5 were used to perform transcriptomics analysis. The cTn-I concentration was tested before, at the end of, and 24 h after surgery. In in vitro study, the expression level of the identified target gene, i.e., THAP11, was studied in H9C2 cells treated with sevoflurane or propofol. Then, we studied cell viability using CCK-8 staining, apoptosis by using flow cytometry, and cell death by lactic acid dehydrogenase (LDH) detection in H9C2 cells exposed to oxygen glucose deprivation/reoxygenation (OGD/R) injury. THAP11 was the most significantly down-regulated gene in the transcriptomics analysis (P < 0.001), as confirmed in validation samples (P = 0.006). THAP11 mRNA levels in atrial muscle specimens were positively associated with cTn-I levels at 24-h postoperatively (determination coefficient = 0.564; P < 0.001). Sevoflurane treatment down-regulated THAP11 in H9C2 cell models, which promoted cell viability, inhibited cell apoptosis, and death in the OGD/R injury cell model. Up-regulation of THAP11 reduced the protective effect of sevoflurane treatment against OGD/R injury. Sevoflurane anesthesia down-regulates the expression of THAP11, which contributes to a cardio-protective effect. THAP11 down-regulation promotes cell viability, and inhibits cell apoptosis and death, thereby protecting again myocardial injury; it may therefore be a novel target for perioperative cardio-protection.
Subject(s)
Cardiotonic Agents/pharmacology , Mitral Valve Insufficiency/drug therapy , Myocardial Reperfusion Injury/drug therapy , Myocytes, Cardiac/drug effects , Repressor Proteins/antagonists & inhibitors , Sevoflurane/pharmacology , Anesthetics, Inhalation/pharmacology , Animals , Apoptosis , Cell Survival , Down-Regulation , Female , Glucose/deficiency , Humans , Male , Middle Aged , Mitral Valve Insufficiency/etiology , Mitral Valve Insufficiency/metabolism , Mitral Valve Insufficiency/pathology , Myocardial Reperfusion Injury/etiology , Myocardial Reperfusion Injury/metabolism , Myocardial Reperfusion Injury/pathology , Myocytes, Cardiac/metabolism , Myocytes, Cardiac/pathology , Oxygen/metabolism , Rats , Repressor Proteins/genetics , Repressor Proteins/metabolismABSTRACT
BACKGROUND: We aimed to explore the biomarkers associated with atrial fibrillation (AF) with mitral regurgitation (MR). METHODS: The gene expression profile data GSE115574 were downloaded from Gene Expression Omnibus database, which were obtained from patients with degenerative MR with AF and sinus rhythm (SR). The differentially expressed genes (DEGs) in samples of AF with MR compared with those of SR with MR were selected, followed by functional enrichment analysis, protein-protein interaction (PPI) network analysis, transcription factor (TF) prediction, and drug-gene interaction prediction. RESULTS: By comparing the genes' expression profiles between AF with MR and SR with MR, 379 DEGs were obtained. The upregulated genes, such as NMNAT2, LDHB, and hexosaminidase subunit beta (HEXB), were significantly enriched in metabolic pathways. Hub genes, such as amyloid beta precursor protein (APP), CDH2, SPP1, and STC2, were significantly associated with functions related to extracellular matrix organization and vitamin D response. Additionally, two TFs, PRDM3 and LSM6, were predicted for the key module genes. APP predicted the most drug molecules, that is, 22 molecules, and SPP1 predicted 10 drug molecules. CONCLUSIONS: Dysregulation of the metabolic pathway may play a critical role in AF with MR. Changes in functions related to the extracellular matrix and vitamin D response may also be associated with AF progression in patients with MR. Furthermore, APP, STC2, and SPP1 may serve as potential therapeutic targets of AF.
Subject(s)
Atrial Fibrillation/genetics , Biomarkers/analysis , Mitral Valve Insufficiency/genetics , Transcriptome , Atrial Fibrillation/metabolism , Gene Expression Regulation , Metabolic Networks and Pathways/genetics , Mitral Valve Insufficiency/metabolismABSTRACT
OBJECTIVE: Primary mitral regurgitation is a valvular lesion in which the left ventricular ejection fraction remains preserved for long periods, delaying a clinical trigger for mitral valve intervention. In this study, we sought to investigate whether adverse left ventricular remodeling occurs before a significant fall in ejection fraction and characterize these changes. METHODS: Sixty-five rats were induced with severe mitral regurgitation by puncturing the mitral valve leaflet with a 23-G needle using ultrasound guidance. Rats underwent longitudinal cardiac echocardiography at biweekly intervals and hearts explanted at 2 weeks (n = 15), 10 weeks (n = 15), 20 weeks (n = 15), and 40 weeks (n = 15). Sixty age- and weight-matched healthy rats were used as controls. Unbiased RNA-sequencing was performed at each terminal point. RESULTS: Regurgitant fraction was 40.99 ± 9.40%, with pulmonary flow reversal in the experimental group, and none in the control group. Significant fall in ejection fraction occurred at 14 weeks after mitral regurgitation induction. However, before 14 weeks, end-diastolic volume increased by 93.69 ± 52.38% (P < .0001 compared with baseline), end-systolic volume increased by 118.33 ± 47.54% (P < .0001 compared with baseline), and several load-independent pump function indices were reduced. Transcriptomic data at 2 and 10 weeks before fall in ejection fraction indicated up-regulation of myocyte remodeling and oxidative stress pathways, whereas those at 20 and 40 weeks indicated extracellular matrix remodeling. CONCLUSIONS: In this rodent model of mitral regurgitation, left ventricular ejection fraction was preserved for a long duration, yet rapid and severe left ventricular dilatation, and biological remodeling occurred before a clinically significant fall in ejection fraction.
Subject(s)
Gene Expression Profiling , Hemodynamics/genetics , Mitral Valve Insufficiency/complications , Mitral Valve/physiopathology , Transcriptome , Ventricular Dysfunction, Left/etiology , Ventricular Function, Left/genetics , Ventricular Remodeling/genetics , Animals , Disease Models, Animal , Male , Mitral Valve Insufficiency/genetics , Mitral Valve Insufficiency/metabolism , Mitral Valve Insufficiency/physiopathology , Myocytes, Cardiac/metabolism , Rats, Sprague-Dawley , Severity of Illness Index , Time Factors , Ventricular Dysfunction, Left/genetics , Ventricular Dysfunction, Left/metabolism , Ventricular Dysfunction, Left/physiopathologyABSTRACT
Ischemic mitral regurgitation (MR) is a frequent complication of myocardial infarction (MI) characterized by adverse remodeling both at the myocardial and valvular levels. Persistent activation of valvular endothelial cells leads to leaflet fibrosis through endothelial-to-mesenchymal transition (EMT). Tenascin C (TNC), an extracellular matrix glycoprotein involved in cardiovascular remodeling and fibrosis, was also identified in inducing epithelial-to-mesenchymal transition. In this study, we hypothesized that TNC also plays a role in the valvular remodeling observed in ischemic MR by contributing to valvular excess EMT. Moderate ischemic MR was induced by creating a posterior papillary muscle infarct (7 pigs and 7 sheep). Additional animals (7 pigs and 4 sheep) served as controls. Pigs and sheep were sacrificed after 6 weeks and 6 months, respectively. TNC expression was upregulated in the pig and sheep experiments at 6 weeks and 6 months, respectively, and correlated well with leaflet thickness (R = 0.68; p < 0.001 at 6 weeks, R = 0.84; p < 0.001 at 6 months). To confirm the translational potential of our findings, we obtained mitral valves from patients with ischemic cardiomyopathy presenting MR (n = 5). Indeed, TNC was also expressed in the mitral leaflets of these. Furthermore, TNC induced EMT in isolated porcine mitral valve endothelial cells (MVEC). Interestingly, Toll-like receptor 4 (TLR4) inhibition prevented TNC-mediated EMT in MVEC. We identified here for the first time a new contributor to valvular remodeling in ischemic MR, namely TNC, which induced EMT through TLR4. Our findings might set the path for novel therapeutic targets for preventing or limiting ischemic MR.
Subject(s)
Endothelial Cells/metabolism , Epithelial-Mesenchymal Transition , Mitral Valve Insufficiency/metabolism , Mitral Valve/metabolism , Myocardial Infarction/complications , Tenascin/metabolism , Aged , Aged, 80 and over , Animals , Cells, Cultured , Disease Models, Animal , Endothelial Cells/pathology , Female , Humans , Male , Middle Aged , Mitral Valve/pathology , Mitral Valve/physiopathology , Mitral Valve Insufficiency/etiology , Mitral Valve Insufficiency/pathology , Mitral Valve Insufficiency/physiopathology , Sheep, Domestic , Signal Transduction , Sus scrofa , Toll-Like Receptor 4/metabolism , Up-RegulationABSTRACT
The molecular mechanism for worsening left ventricular (LV) function after mitral valve (MV) repair for chronic mitral regurgitation remains unknown. We wished to assess the LV transcriptome and identify determinants associated with worsening LV function post-MV repair. A total of 13 patients who underwent MV repair for chronic primary mitral regurgitation were divided into two groups, preserved LV function (N = 8) and worsening LV function (N = 5), for the study. Specimens of LV from the patients taken during surgery were used for the gene microarray study. Cardiomyocyte cell line HL-1 cells were transfected with gene-containing plasmids and further evaluated for mRNA and protein expression, apoptosis, and contractile protein degradation. Of 67,258 expressed sequence tags, microarrays identified 718 genes to be differentially expressed between preserved-LVF and worsening-LVF, including genes related to the protein ubiquitination pathway, bone morphogenetic protein (BMP) receptors, and regulation of eIF4 and p70S6K signaling. In addition, worsening-LVF was associated with altered expressions of genes pathologically relevant to heart failure, such asdownregulated apelin receptors and upregulated peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PPARGC1A). HL-1 cardiomyocyte cells transfected with ubiquitination-related genes demonstrated activation of the protein ubiquitination pathwaywith an increase in the ubiquitin activating enzyme E1 (UAE-E1). It also led to increased apoptosis, downregulated and ubiquitinated X-linked inhibitor of apoptosis protein (XIAP), and reduced cell viability. Overexpression of ubiquitination-related genes also resulted in degradation and increased ubiquitination of α-smooth muscle actin (SMA). In conclusion, worsening-LVF presented differential gene expression profiles from preserved-LVF after MV repair. Upregulation of protein ubiquitination-related genes associated with worsening-LVF after MV repair may exert adverse effects on LV through increased apoptosis and contractile protein degradation.
Subject(s)
Heart Failure/metabolism , Mitral Valve Insufficiency/metabolism , Mitral Valve/metabolism , Myocytes, Cardiac/metabolism , Ubiquitin/metabolism , Ventricular Function, Left/genetics , Actins/metabolism , Adult , Aged , Apoptosis/genetics , Bone Morphogenetic Protein Receptors/genetics , Bone Morphogenetic Protein Receptors/metabolism , Cell Line , Cell Survival/genetics , Female , Gene Expression Regulation/genetics , Heart Failure/genetics , Heart Ventricles/physiopathology , Humans , Male , Middle Aged , Mitral Valve/enzymology , Mitral Valve/surgery , Mitral Valve Insufficiency/enzymology , Mitral Valve Insufficiency/genetics , Mitral Valve Insufficiency/physiopathology , Oligonucleotide Array Sequence Analysis , Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha/genetics , Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha/metabolism , Ribosomal Protein S6 Kinases, 70-kDa/genetics , Ribosomal Protein S6 Kinases, 70-kDa/metabolism , Signal Transduction/genetics , Ubiquitin/genetics , Ubiquitin-Activating Enzymes/genetics , Ubiquitin-Activating Enzymes/metabolism , Ubiquitination/genetics , X-Linked Inhibitor of Apoptosis Protein/genetics , X-Linked Inhibitor of Apoptosis Protein/metabolismABSTRACT
Myxomatous mitral valve degeneration (MMVD) is a leading cause of valve repair or replacement secondary to the production of mitral regurgitation, cardiac enlargement, systolic dysfunction, and heart failure. The pathophysiology of myxomatous mitral valve degeneration is complex and incompletely understood, but key features include activation and transformation of mitral valve (MV) valvular interstitial cells (VICs) into an active phenotype leading to remodeling of the extracellular matrix and compromise of the structural components of the mitral valve leaflets. Uncovering the mechanisms behind these events offers the potential for therapies to prevent, delay, or reverse myxomatous mitral valve degeneration. One such mechanism involves the neurotransmitter serotonin (5HT), which has been linked to development of valvulopathy in a variety of settings, including valvulopathy induced by serotonergic drugs, Serotonin-producing carcinoid tumors, and development of valvulopathy in laboratory animals exposed to high levels of serotonin. Similar to humans, the domestic dog also experiences naturally occurring myxomatous mitral valve degeneration, and in some breeds of dogs, the lifetime prevalence of myxomatous mitral valve degeneration reaches 100%. In dogs, myxomatous mitral valve degeneration has been associated with high serum serotonin, increased expression of serotonin-receptors, autocrine production of serotonin within the mitral valve leaflets, and downregulation of serotonin clearance mechanisms. One pathway closely associated with serotonin involves transforming growth factor beta (TGF-ß) and the two pathways share a common ability to activate mitral valve valvular interstitial cells in both humans and dogs. Understanding the role of serotonin and transforming growth factor beta in myxomatous mitral valve degeneration gives rise to potential therapies, such as 5HT receptor (5HT-R) antagonists. The main purposes of this review are to highlight the commonalities between myxomatous mitral valve degeneration in humans and dogs, with specific regards to serotonin and transforming growth factor beta, and to champion the dog as a relevant and particularly valuable model of human disease that can accelerate development of novel therapies.
Subject(s)
Dog Diseases/metabolism , Mitral Valve Insufficiency/veterinary , Mitral Valve Prolapse/metabolism , Mitral Valve/metabolism , Serotonin/metabolism , Transforming Growth Factor beta/metabolism , Animals , Dog Diseases/pathology , Dogs , Humans , Mitral Valve/pathology , Mitral Valve Insufficiency/metabolism , Mitral Valve Insufficiency/pathology , Mitral Valve Prolapse/pathology , Signal Transduction , Species SpecificityABSTRACT
AIMS: In mitral valve prolapse (MVP), leaflet thickening has recently been suggested to be due, in addition to a myxomatous degeneration, to the presence of a superimposed tissue (SIT), defined as an additional fibrous layer on top of the original leaflet. The mechanisms of SIT formation are currently unknown. We hypothesized that SIT formation would result from excessive leaflet stress and we used a unique ex vivo model to assess the correlation between leaflet remodelling and the type and location of mechanical stress and to elucidate the mechanisms underlying SIT formation. METHODS AND RESULTS: Human diseased mitral valves (MVs; n = 21) were histologically analysed for SIT formation and original leaflet thickening. The SIT comprised of various compositions of extracellular matrix and could reach more than 50% of total leaflet thickness. Original leaflet and SIT thickness did not show significant correlation (r = -0.27, P = 0.23), suggesting different regulatory mechanisms. To study the role of the mechanical environment on MV remodelling, mouse MV were cultured in their natural position in the heart and subjected to various haemodynamic conditions representing specific phases of the cardiac cycle and the MVP configuration. SIT formation was induced in the ex vivo model, mostly present on the atrial side, and clearly dependent on the duration, type, and extent of mechanical stress. Specific stainings and lineage tracing experiments showed that SIT comprises of macrophages and myofibroblasts and is associated with the activation of the transforming growth factor-beta and bone morphogenetic protein signalling pathways. Migration of valvular interstitial cells and macrophages through breakages of the endothelial cell lining contributed to SIT formation. CONCLUSIONS: Mechanical stresses induce specific cellular and molecular changes in the MV that result in SIT formation. These observations provide the first insights in the mechanism of SIT formation and represent an initial step to identify potential novel and early treatment for MVP.
Subject(s)
Hemodynamics , Mechanotransduction, Cellular , Mitral Valve Insufficiency/pathology , Mitral Valve Prolapse/pathology , Mitral Valve/pathology , Aged , Animals , Bone Morphogenetic Proteins/metabolism , Cell Movement , Endothelial Cells/metabolism , Endothelial Cells/pathology , Female , Humans , Macrophages/metabolism , Macrophages/pathology , Male , Mice, Transgenic , Middle Aged , Mitral Valve/metabolism , Mitral Valve/physiopathology , Mitral Valve Insufficiency/metabolism , Mitral Valve Insufficiency/physiopathology , Mitral Valve Prolapse/metabolism , Mitral Valve Prolapse/physiopathology , Phosphorylation , Smad Proteins/metabolism , Stress, Mechanical , Time Factors , Tissue Culture Techniques , Transforming Growth Factor beta/metabolismABSTRACT
Chronic mitral valve disease (CMVD) is the most common cardiovascular disease in dogs, causing decreased cardiac output that results in poor tissue perfusion and tissue damage to kidneys, pancreas, and other organs. The purpose of this study was to evaluate the relationships between heart disease severity and N-terminal pro B-type natriuretic peptide (NT-proBNP) and lipase in dogs with CMVD, as well as to evaluate longitudinal changes in these values. A total of 84 dogs participated in this 2015 to 2017 study. Serum values of NT-proBNP and lipase were analyzed; radiography was used to measure the vertebral heart score and assess various echocardiographic values. NT-proBNP showed a strong positive correlation with increasing stage of heart disease; lipase showed a mild positive correlation with heart disease stage. When the three values (NT-proBNP, lipase and month) were continuously measured at 6-month intervals, all showed a correlation with the increasing length of the disease.
Subject(s)
Dog Diseases/physiopathology , Lipase/blood , Mitral Valve Insufficiency/veterinary , Natriuretic Peptide, Brain/blood , Peptide Fragments/blood , Animals , Chronic Disease , Dog Diseases/enzymology , Dog Diseases/metabolism , Dogs , Echocardiography , Longitudinal Studies , Mitral Valve Insufficiency/enzymology , Mitral Valve Insufficiency/metabolism , Mitral Valve Insufficiency/physiopathology , Republic of KoreaABSTRACT
Background Mitral valve prolapse (MVP) is a common heart valve disease, the most frequent indication for valve repair or replacement. MVP is characterized by excess extracellular matrix secretion and cellular disorganization, which leads to bulky valves that are unable to coapt correctly during ventricular systole resulting in mitral regurgitation, and it is associated with sudden cardiac death. Here we aim to characterize globally the biological mechanisms underlying genetic susceptibility to MVP to better characterize its triggering mechanisms. Methods We applied i-GSEA4GWAS and DEPICT, two pathway enrichment tools to MVP genome-wide association studies. We followed-up the association with MVP in an independent dataset of cases and controls. This research was conducted using the UK Biobank Resource. Immunohistochemistry staining for Glis1 (GLIS family zinc finger 1) was conducted in developing heart of mice. Knockdown of Glis1 using morpholinos was performed in zebrafish animals 72 hours postfertilization. Results We show that genes at risk loci are involved in biological functions relevant to actin filament organization, cytoskeleton biology, and cardiac development. The enrichment for positive regulation of transcription, cell proliferation, and migration motivated the follow-up of GLIS1, a transcription factor from the Krüppel-like zinc finger family. In combination with previously available data, we now report a genome-wide significant association with MVP (odds ratio, 1.20; P=4.36×10-10), indicating that Glis1 is expressed during embryonic development predominantly in nuclei of endothelial and interstitial cells of mitral valves in mouse. We also show that Glis1 knockdown causes atrioventricular regurgitation in developing hearts in zebrafish. Conclusions Our findings define globally molecular and cellular mechanisms underlying common genetic susceptibility to MVP and implicate established and unprecedented mechanisms. Through the GLIS1 association and function, we point at regulatory functions during cardiac development as common mechanisms to mitral valve degeneration.
Subject(s)
DNA-Binding Proteins/genetics , Mitral Valve Prolapse/genetics , Transcription Factors/genetics , Animals , DNA-Binding Proteins/metabolism , Female , Follow-Up Studies , Genetic Predisposition to Disease , Genome-Wide Association Study , Heart/growth & development , Heart Valves/growth & development , Heart Valves/metabolism , Humans , Male , Mice , Mitral Valve Insufficiency/etiology , Mitral Valve Insufficiency/metabolism , Mitral Valve Prolapse/complications , Mitral Valve Prolapse/embryology , Mitral Valve Prolapse/metabolism , Polymorphism, Single Nucleotide , Transcription Factors/metabolism , United Kingdom , ZebrafishABSTRACT
INTRODUCTION: Mitral valve disease (MVD), including mitral valve regurgitation (MR) and mitral valve stenosis (MS), is a chronic and progressive cardiac malady. However, the metabolic alterations in MVD is not well-understood till now. The current gold standard diagnostic test, transthoracic echocardiography, has limitations on high-throughput measurement and lacks molecular information for early diagnosis of the disease. OBJECTIVE: The present study aimed to investigate the biochemical alterations and to explore their diagnostic potential for MVD. METHODS: Plasma metabolic profile derangements and their diagnostic potential were non-invasively explored in 34 MR and 20 MS patients against their corresponding controls, using high-throughput NMR-based untargeted metabolomics. RESULTS: Eighteen differential metabolites were identified for MR and MS patients respectively, on the basis of multivariate and univariate data analysis, which were mainly involved in energy metabolism, amino acid metabolism, calcium metabolism and inflammation. These differential metabolites, notably the significantly down-regulated formate and lactate, showed high diagnostic potential for MVD by using Spearman's rank-order correlation analysis and ROC analysis. CONCLUSIONS: To the best of our knowledge, the present study is the first one that explores the metabolic derangements and their diagnostic values in MVD patients using metabolomics. The findings indicated that metabolic disturbance occurred in MVD patients, with plasma formate and lactate emerged as important candidate biomarkers for MVD.
Subject(s)
Mitral Valve Insufficiency/metabolism , Mitral Valve Stenosis/metabolism , Adult , Aged , Amino Acids , Female , Heart/physiology , Heart Valve Diseases/diagnosis , Heart Valve Diseases/metabolism , Humans , Male , Metabolomics/methods , Middle Aged , Mitral Valve/metabolism , Mitral Valve/physiopathology , Plasma/chemistry , ROC CurveABSTRACT
OBJECTIVES: This study aims to correlate subclinical echocardiographic features with the clinical, laboratory, and therapeutic profiles of the patients to characterize risks for systemic lupus erythematosus (SLE) cardiac diseases. METHODS: The study included 59 SLE patients. Demographic data, disease characteristics, and current therapies were recorded, and the anthropometric measurements and routine laboratory tests were performed. The disease activity by the SLE Disease Activity Index-2K (SLEDAI2K) and the presence of metabolic syndrome (MetS) were assessed. Two-dimensional echocardiography was performed. RESULTS: The mean age of the patients was 31.3 ± 10.5 years, and the disease duration was 5.18 ± 4.1 years. 86.4% of the patients were females. Cardiac presentations by echocardiography were mainly mitral regurgitation (33.9%), tricuspid regurgitation (32.2%), mitral thickening (18.6%), aortic thickening (13.6%), pericardial effusion (13.6%), and pulmonary hypertension (8.5%) in order of frequency. The frequency of different echocardiographic findings with respect to other clinical phenotypes showed peaks with renal disease, MetS, and leukopenia. Components of MetS (triglycerides, high systolic blood pressure) and avascular necrosis were significant predictors for pericardial diseases (OR=1.011 CI 95% 1-1.022, p=0.046, OR=1.157 CI 95% 1.025-1.307, p=0.018, and OR=74.78 CI 95% 2.52-2215.76, p=0.013, respectively), and it is likely that hydroxychloroquine was protective against them. Age of the patients was a significant predictor for tricuspid regurgitation (OR=1.063 CI 95% 1.004-1.126, p=0.036). Mucosal ulcers were negative predictors for mitral thickening and regurgitation (OR=0.2 CI 95% 0.059-0.673, p=0.009). The use of corticosteroids appeared to protect against a number of valve lesions especially tricuspid regurgitation (OR=0.299 CI 95% 0.088-1.019, p=0.054). CONCLUSION: This study highlighted different echocardiographic features and identified clinical predictors of different cardiac pathologies aiming to determine patients at risk and improve the prognosis of SLE cardiac diseases.
Subject(s)
Heart Valve Diseases/metabolism , Lupus Erythematosus, Systemic/metabolism , Metabolic Syndrome/metabolism , Mitral Valve Insufficiency/metabolism , Adult , Blood Cell Count , Blood Sedimentation , Cholesterol/blood , Echocardiography, Doppler , Female , Heart/diagnostic imaging , Heart/physiopathology , Heart Valve Diseases/blood , Heart Valve Diseases/complications , Heart Valve Diseases/physiopathology , Humans , Hypertension, Pulmonary/blood , Hypertension, Pulmonary/complications , Hypertension, Pulmonary/physiopathology , Lipoproteins, HDL/blood , Lipoproteins, LDL/blood , Lupus Erythematosus, Systemic/blood , Lupus Erythematosus, Systemic/complications , Lupus Erythematosus, Systemic/physiopathology , Male , Metabolic Syndrome/blood , Metabolic Syndrome/complications , Metabolic Syndrome/physiopathology , Middle Aged , Mitral Valve Insufficiency/blood , Mitral Valve Insufficiency/complications , Mitral Valve Insufficiency/physiopathology , Pericardial Effusion/blood , Pericardial Effusion/complications , Pericardial Effusion/physiopathology , Triglycerides/blood , Uric Acid/bloodABSTRACT
BACKGROUND: Mitral valve (MV) regurgitation constitutes an increasing burden of adult and pediatric cardiac disease tending to worsen over time. Whether altered mechanical forces on leaflets cause valve disease is unknown. Here we show that MV leaflet coaptive strain disruption alters expression of genes critical to leaflet homeostasis. METHODS: We used a flow-culture bioreactor of rat MVs with flow-induced cyclic coaptation (cycling valve group; n = 4) or in a sustained open state (open valve group; n = 4). After 3 days of culture, leaflet RNA expression was profiled. RESULTS: More than 48 genes exhibited markedly changed expression when coaptive leaflet strain was disrupted for 3 days (change >fourfold; p < 0.05; cycling vs open valves). Genes exhibiting highly altered expression included Angpt2, Vegf, Cd74, RT1-Da (HLA-DRA), and Igfbp3. Pathway analysis indicated the most significant signaling pathways regulating the expression changes were Hif1α and Tnfα when MV closure was disrupted. CONCLUSIONS: Disruption of normal MV coaptive strain markedly alters the expression of leaflet genes, demonstrating that cyclic strain is critically important to leaflet homeostasis. We demonstrate a pattern of MV gene expression changes in which hypoxia signaling is prominently increased in response to disrupted strain cycles. Coaptive strain regulation of MV leaflet homeostasis implicates altered strain as a mechanism potentially initiating valve disease. Early repair may prevent progression of disease driven by altered coaptation.
Subject(s)
Homeostasis/physiology , Mitral Valve Insufficiency/metabolism , Mitral Valve/metabolism , RNA/genetics , Animals , Biomechanical Phenomena , Bioreactors , Cells, Cultured , Disease Models, Animal , Female , Gene Expression Regulation , Mitral Valve Insufficiency/genetics , Mitral Valve Insufficiency/physiopathology , RNA/biosynthesis , Rats , Rats, Sprague-Dawley , Stress, MechanicalABSTRACT
BACKGROUND: Lipid expression is increased in the atrial myocytes of mitral regurgitation (MR) patients. This study aimed to investigate key regulatory genes and mechanisms of atrial lipotoxic myopathy in MR. METHODS: The HL-1 atrial myocytes were subjected to uniaxial cyclic stretching for eight hours. Fatty acid metabolism, lipoprotein signaling, and cholesterol metabolism were analyzed by PCR assay (168 genes). RESULTS: The stretched myocytes had significantly larger cell size and higher lipid expression than non-stretched myocytes (all p < 0.001). Fatty acid metabolism, lipoprotein signaling, and cholesterol metabolism in the myocytes were analyzed by PCR assay (168 genes). In comparison with their counterparts in non-stretched myocytes, seven genes in stretched monocytes (Idi1, Olr1, Nr1h4, Fabp2, Prkag3, Slc27a5, Fabp6) revealed differential upregulation with an altered fold change >1.5. Nine genes in stretched monocytes (Apoa4, Hmgcs2, Apol8, Srebf1, Acsm4, Fabp1, Acox2, Acsl6, Gk) revealed differential downregulation with an altered fold change <0.67. Canonical pathway analysis, using Ingenuity Pathway Analysis software, revealed that the only genes in the "superpathway of cholesterol biosynthesis" were Idi1 (upregulated) and Hmgcs2 (downregulated). The fraction of stretched myocytes expressing Nile red was significantly decreased by RNA interference of Idi1 (p < 0.05) and was significantly decreased by plasmid transfection of Hmgcs2 (p = 0.004). CONCLUSIONS: The Idi1 and Hmgcs2 genes have regulatory roles in atrial lipotoxic myopathy associated with atrial enlargement.
Subject(s)
Carbon-Carbon Double Bond Isomerases/genetics , Hydroxymethylglutaryl-CoA Synthase/genetics , Lipid Metabolism/genetics , Mitral Valve Insufficiency/genetics , Cell Line , Cholesterol/genetics , Cholesterol/metabolism , Flow Cytometry , Gene Expression Regulation/genetics , Heart Atria/metabolism , Heart Atria/physiopathology , Hemiterpenes , Humans , Lipids/genetics , Lipoproteins/genetics , Lipoproteins/metabolism , Mitral Valve Insufficiency/metabolism , Mitral Valve Insufficiency/physiopathology , Myocytes, Cardiac/metabolism , Myocytes, Cardiac/pathology , Signal TransductionABSTRACT
Surgical repair or replacement of the mitral valve is currently the only recommended therapy for severe primary mitral regurgitation. The chronic elevation of wall stress caused by the resulting volume overload leads to structural remodelling of the muscular, vascular and extracellular matrix components of the myocardium. These changes are initially compensatory but in the long term have detrimental effects, which ultimately result in heart failure. Understanding the changes that occur in the myocardium due to volume overload at the molecular and cellular level may lead to medical interventions, which potentially could delay or prevent the adverse left ventricular remodelling associated with primary mitral regurgitation. The pathophysiological changes involved in left ventricular remodelling in response to chronic primary mitral regurgitation and the evidence for potential medical therapy, in particular beta-adrenergic blockers, are the focus of this review.
Subject(s)
Adrenergic beta-Antagonists/therapeutic use , Heart Ventricles/drug effects , Mitral Valve Insufficiency/drug therapy , Ventricular Function, Left/drug effects , Ventricular Remodeling/drug effects , Adrenergic beta-Antagonists/adverse effects , Animals , Chronic Disease , Extracellular Matrix/drug effects , Extracellular Matrix/metabolism , Extracellular Matrix/pathology , Heart Ventricles/metabolism , Heart Ventricles/pathology , Heart Ventricles/physiopathology , Humans , Inflammation Mediators/metabolism , Mechanotransduction, Cellular/drug effects , Mitral Valve Insufficiency/metabolism , Mitral Valve Insufficiency/pathology , Mitral Valve Insufficiency/physiopathology , Oxidative Stress/drug effects , Recovery of Function , Treatment OutcomeABSTRACT
INTRODUCTION Although there are several known risk factors of cardiovascular diseases (CVDs), the search for new factors continues. In recent years, clinical trials have reported vitamin D and other calcium (Ca) and phosphate (P) metabolism disorders as potential new cardiovascular risk factors, but literature data on this association are limited. OBJECTIVES We aimed to assess the extent of Ca and P metabolism disorders in patients with mitral regurgitation (MR) and potential role of these disorders as risk factors of CVD. PATIENTS AND METHODS We enrolled adult patients with significant MR (vena contracta >3 mm, effective orifice area >0.2 cm2, and MR volume >30 ml/s) hospitalized in our department between July and September 2013. Anthropometric data were collected. Moreover, all patients underwent blood and urine analysis, transthoracic echocardiography, and 6minute walking test. RESULTS A total of 99 patients were enrolled (median age, 75 years; [Q1-Q3, 66.0-81.5]; women, 35.4%). The median serum Ca level corrected by albumin was 3.22 mmol/l [Q1-Q3, 3.14-3.27]. The mean (SD) serum ionized Ca level corrected by pH was 1.05 (0.08) mmol/l. The median levels of parathyroid hormone (PTH) and 25(OH)D3 were 63.10 pg/ml [Q1-Q3, 40.95-88.55] and 14.80 ng/ml [Q1-Q3, 9.93-20.12], respectively. Patients with a history of heart failure (HF) with reduced ejection fraction (New York Heart Association class IV), shorter distance in the 6minute walking test, lower left ventricular ejection fraction, and larger left ventricular enddiastolic diameter had significantly higher probability of elevated PTH levels. CONCLUSIONS Disorders of Ca and P metabolism in patients with significant MR are a noteworthy clinical problem. Our study is the first to systematically describe these disorders in patients with CVD. However, larger studies are needed to confirm the significance of our results.